Discovery of JNJ-1802, a First-in-Class Pan-Serotype Dengue Virus NS4B Inhibitor.
J Med Chem
; 67(5): 4063-4082, 2024 Mar 14.
Article
em En
| MEDLINE
| ID: mdl-38482827
ABSTRACT
Dengue is a global public health threat, with about half of the world's population at risk of contracting this mosquito-borne viral disease. Climate change, urbanization, and global travel accelerate the spread of dengue virus (DENV) to new areas, including southern parts of Europe and the US. Currently, no dengue-specific small-molecule antiviral for prophylaxis or treatment is available. Here, we report the discovery of JNJ-1802 as a potent, pan-serotype DENV inhibitor (EC50's ranging from 0.057 to 11 nM against the four DENV serotypes). The observed oral bioavailability of JNJ-1802 across preclinical species, its low clearance in human hepatocytes, the absence of major in vitro pharmacology safety alerts, and a dose-proportional increase in efficacy against DENV-2 infection in mice were all supportive of its selection as a development candidate against dengue. JNJ-1802 is being progressed in clinical studies for the prevention or treatment of dengue.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Dengue
/
Vírus da Dengue
/
Hidrocarbonetos Halogenados
/
Indóis
Idioma:
En
Ano de publicação:
2024
Tipo de documento:
Article